Consistently, CSF1R inhibition enhanced the therapeutic activity of a PD-1-specific mAb in subcutaneous xenograft mouse models of CRC by improving the infiltration and activation of CD8+ T cells in tumors [67]. The gene discussed is CD8A; the disease is colorectal carcinoma.